Nitric Oxide Consumption as a Predictor of Vasospasm in Subarachnoid Hemorrhage

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT07614906
Status
Recruiting
Apply to this trial

Conditions

  • Aneurysmal Subarachnoid Hemorrhage
  • Cerebral Vasospasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Study Details

The goal of this observational study is to understand if angiographic cerebral vasospasm (CV) can be predicted by levels of nitric oxide (NO) consumption in patients with aneurysmal subarachnoid hemorrhage (SAH). To reach this goal, the investigators will compare NO consumption levels in SAH and non-SAH patients. NO consumption levels will be analyzed from samples of participants' cerebral spinal fluid (CSF).

Key Dates

Start date
Mar 3, 2024
Status verified
May 2026
Primary completion
May 31, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
40 participants (estimated)

Arms

  • Arm: Aneurysmal subarachnoid hemorrhage
    Patients admitted to the Intensive Care Unit following spontaneous aneurysmal subarachnoid hemorrhage
  • Arm: Control
    Patients without neurological comorbidities undergoing spinal anesthesia in the operating room

Primary Outcome Measure

Nitric oxide consumption [ Time Frame: Daily for 15 days following aneurysmal subarachnoid hemorrhage; for controls, once at initiation of spinal anesthesia ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02114
Lorenzo Berra, MD
[email protected]
617-726-3030

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital· Boston, MA

Related Studies